Abstract
To further optimize a clinical candidate 5 (EW-7197), a series of 5-(3-, 4-, or 5-fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles 19a-l have been synthesized and evaluated for their TGF-β type I receptor kinase (ALK5) and p38α MAP kinase inhibitory activity in an enzyme assay. The 5-(5-fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles 19h-l displayed the similar level of potency to that of 5 against both ALK5 (IC50=7.68-13.70 nM) and p38α MAP kinase (IC50=1240-3370 nM). Among them, 19j inhibited ALK5 with IC50 value of 7.68 nM in a kinase assay and displayed 82% inhibition at 100 nM in a luciferase reporter assay.
Keywords:
ALK5 inhibitor; Cancer; Fibrosis; Kinase assay; TGF-β.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cell Line
-
Enzyme Assays
-
Genes, Reporter
-
Humans
-
Imidazoles / chemical synthesis*
-
Imidazoles / pharmacology
-
Luciferases / genetics
-
Mitogen-Activated Protein Kinase 14 / antagonists & inhibitors
-
Protein Kinase Inhibitors / chemical synthesis*
-
Protein Kinase Inhibitors / pharmacology
-
Protein Serine-Threonine Kinases / antagonists & inhibitors*
-
Pyridines / chemical synthesis*
-
Pyridines / pharmacology
-
Receptor, Transforming Growth Factor-beta Type I
-
Receptors, Transforming Growth Factor beta / antagonists & inhibitors*
-
Triazoles / chemical synthesis*
-
Triazoles / pharmacology
Substances
-
Imidazoles
-
Protein Kinase Inhibitors
-
Pyridines
-
Receptors, Transforming Growth Factor beta
-
Triazoles
-
Luciferases
-
Protein Serine-Threonine Kinases
-
Mitogen-Activated Protein Kinase 14
-
Receptor, Transforming Growth Factor-beta Type I
-
TGFBR1 protein, human